Vaxart, Inc. (VXRT): Entry into a Material Definitive Agreement
Vaxart, Inc. (VXRT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ea029670901ex10-1.htm COOPERATION AGREEMENT, DATED JULY 1, 2026 Exhibit 10.1 COOPERATION AGREEMENT This COOPERATION AGREEMENT (this “ Agreement ”) is made and entered into as of July 1, 2026, by and among Vaxart, Inc., a Delaware corporation (the “ Company ”), on the on
How this was made
The 30-second read
Why it matters
By withdrawing the nomination notice and books/records demand, the stockholder group ends the immediate proxy contest and litigation-like pressure. The agreement also establishes a timeline and mutual process to identify and appoint a new independent director to the board and NGC.
Market read
This is a governance/activism settlement that may reduce near-term uncertainty around the 2026 annual meeting, but it does not provide new clinical or financial catalysts.
What to watch
The agreement’s practical impact depends on who the mutually agreed independent director is and whether the process meaningfully changes board oversight or strategy.
Background
The 8-K reports entry into a cooperation agreement between Vaxart and a stockholder group that previously nominated directors and demanded access to company books/records ahead of the 2026 annual meeting.
Ticker impact
Vaxart entered a material definitive cooperation agreement withdrawing a proxy nomination and books/records demand tied to its 2026 annual meeting.
Near-term impact likely limited; any reaction would be driven by investor perception of governance stability rather than fundamentals.
The filing is a governance/settlement disclosure (withdrawal of nominations and demands) plus a defined board-composition process, but it does not include financial guidance, clinical, or deal economics.
Market effects
Limited read-across; governance settlements are company-specific and typically do not re-rate the biotech/biopharma sector.
None.
None.
Counterpoint
Investors may discount the agreement as a temporary truce that still implies underlying shareholder dissatisfaction and potential future activism.
Key entities
- CompanyVaxart, Inc.
Subject of the 8-K; entered the cooperation agreement and will coordinate board composition changes.
- Shareholder groupStockholder Group (Daniel P. Houle, Mark Silverberg, Matthew M. Wallace, Patrice Raffy, Q3 Nominees Pty Ltd., Marc Eustace Pereira)
Previously held ~0.6% and submitted nominations and a books/records demand; withdraws these under the agreement.
- Governance advisorsInstitutional Shareholder Services Inc. (ISS) and Glass Lewis
Referenced for the ‘overboarded’ director policy constraint for the new director.
